OnlineBusinessBureau.com
We are not the Better Business Bureau. We're better!
 
   About Us
   Our Ratings
   Look up a Company
   File a Complaint
   Complaint Resolution
     Center
   Resources
   Membership - Join Now!
   Member Login
   Testimonials
   Contact Us

1,846,404 companies
in our database.

Join our weekly
Consumer Fraud
Alert Newsletter



Our members proudly
display this seal!

News Releases

Back

Now Available: Amyloidosis - Pipeline Review, H2 2014

Global Markets Direct's, 'Amyloidosis - Pipeline Review, H2 2014', provides an overview of the Amyloidosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Amyloidosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyloidosis and special features on late-stage and discontinued projects.

Full Report Details at
 - http://www.fastmr.com/prod/872734_amyloidosis_pipeline_review_h2_2014.aspx?afid=101

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

 * The report provides a snapshot of the global therapeutic landscape of Amyloidosis
 * The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
 * The report reviews key players involved in the therapeutics development for Amyloidosis and enlists all their major and minor projects
 * The report summarizes all the dormant and discontinued pipeline projects
 * A review of the Amyloidosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
 * Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
 * A detailed assessment of monotherapy and combination therapy pipeline projects
 * Coverage of the Amyloidosis pipeline on the basis of target, MoA, route of administration and molecule type
 * Latest news and deals relating related to pipeline products

Reasons to Get this Report

 * Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
 * Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
 * Develop strategic initiatives by understanding the focus areas of leading companies
 * Identify and understand important and diverse types of therapeutics under development for Amyloidosis
 * Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
 * Devise corrective measures for pipeline projects by understanding Amyloidosis pipeline depth and focus of Indication therapeutics
 * Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 * Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned in this Report: GlaxoSmithKline plc, Celgene Corporation, Onyx Pharmaceuticals, Inc., Bellus Health Inc., ProteoTech, Inc., Auven Therapeutics Management L.L.L.P, NeuroPhage Pharmaceuticals, Inc., SOM Biotech SL

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Amyloidosis Overview
Therapeutics Development
Pipeline Products for Amyloidosis - Overview
Pipeline Products for Amyloidosis - Comparative Analysis
Amyloidosis - Therapeutics under Development by Companies
Amyloidosis - Therapeutics under Investigation by Universities/Institutes
Amyloidosis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Amyloidosis - Products under Development by Companies
Amyloidosis - Products under Investigation by Universities/Institutes
Amyloidosis - Companies Involved in Therapeutics Development
GlaxoSmithKline plc
Celgene Corporation
Onyx Pharmaceuticals, Inc.
Bellus Health Inc.
ProteoTech, Inc.
Auven Therapeutics Management L.L.L.P
NeuroPhage Pharmaceuticals, Inc.
SOM Biotech SL
Amyloidosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
eprodisate disodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SOM-0226 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pomalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
carfilzomib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PTI-110 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-2315698 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-2398852 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-2315698 + GSK-2398852 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NPT-005 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for AL Amyloidosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Full Table of Contents is available at:
-- http://www.fastmr.com/prod/872734_amyloidosis_pipeline_review_h2_2014.aspx?dt=t&afid=101

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available.  Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

 


Credit Secrets Bible

Get Paid for
Doing Surveys





The Online Business Bureau -- 21441 Pacific Boulevard -- Suite 200 -- Sterling, VA 20166 -- 202-558-5282
News Releases |  News Articles |  Financial Calculators |  Contact Us |  Privacy Policy | Terms of Use & Legal Notice
Copyright © 2017 Online Business Bureau, L. C.. All Rights Reserved.
We are not affiliated with the Council of Better Business Bureaus, Inc.